Xencor and CSL Limited establish antibody optimization collaboration

Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd. The collaboration will provide CSL with access to Xencor's XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.

During the research phase of the collaboration, Xencor will provide CSL with the opportunity to utilize the technology broadly across its antibody candidate pipeline. Xencor has granted CSL several commercial licenses to move product candidates into development and ultimately commercialization which incorporate Xencor's XmAb technology. In addition to an upfront payment, CSL will pay Xencor development milestone payments and product royalties for each product commercialized that incorporates the Xencor technology.

"We are excited to collaborate with our CSL colleagues and enable their antibody products through the use of our XmAb technology," commented Bassil Dahiyat, Ph.D., Xencor's chief executive officer.

"We are pleased that the market is recognizing the preferred development friendly solution to increasing antibody effector function that Xencor offers," commented James Posada, Ph.D., MBA, Xencor's acting chief business officer.

About XmAb ADCC technology

The XmAb platform can increase the potency of therapeutic antibodies by specifically engaging the body's immune system against target antigen cells. A proprietary suite of XmAb Fc variants allows the selective improvement of antibody cytotoxic properties by enhancing antibody-dependent cell cytotoxicity (ADCC), phagocytosis and/or complement activation. Increased antibody potency has the potential to improve antibody efficacy in a variety of therapeutic areas, including oncology, infectious disease and autoimmune disorders. The technology offers the broadest range of specific Fc receptor activation currently available in the most "development friendly" format which can be used with any production cell line system and does not involve complex manipulations of highly heterogeneous carbohydrate molecules.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
New antibody shows promise in reducing tau proteins associated with Alzheimer's disease